BioCardia (BCDA) risk factors

79 risks, 1 reworded since the prior year. The risk section remained largely unchanged, with only minor edits to tax carryforward disclosures.

79 risks. BioCardia is a clinical-stage regenerative medicine company with a net loss of $7.9 million for 2024 and an accumulated deficit of $160.1 million. The company's long-term viability depends on the successful development and commercialization of the CardiAMP Cell Therapy System. The FDA premarket approval pathway for CardiAMP and the recent recommendation by the DSMB to pause the Phase III trial introduce significant regulatory uncertainty.